• Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Pain and continued opioid use in individuals receiving buprenorphine-naloxone for opioid detoxification: secondary analyses from the Clinical Trials Network.

Pain complaints are common among individuals with opioid dependence. However, few studies investigate pain during opioid detoxification or the impact this pain has on continued opioid use. This secondary analysis utilized data from two Clinical Trials Network randomized controlled trials of buprenorphine-naloxone for short-term opioid detoxification to examine the extent to which pain was associated with continued opioid use during and immediately following a 13-day detoxification protocol. At follow-up, more severe pain was associated with a greater number of self-reported days of opioid use during the prior 30 days (p < .05) but was not associated with urine toxicology results collected at follow-up. These results, although mixed, have potentially important clinical implications for assessing and addressing pain during opioid detoxification. Pain that is experienced during and immediately following medically monitored detoxification may be associated with continued opioid use. These findings lend further support for continued research on pain among patients with opioid dependence.

Pubmed ID: 20307799

Authors

  • Potter JS
  • Chakrabarti A
  • Domier CP
  • Hillhouse MP
  • Weiss RD
  • Ling W

Journal

Journal of substance abuse treatment

Publication Data

June 23, 2010

Associated Grants

  • Agency: NIDA NIH HHS, Id: DA 13045
  • Agency: NIDA NIH HHS, Id: K23 DA0222297
  • Agency: NIDA NIH HHS, Id: K23 DA022297
  • Agency: NIDA NIH HHS, Id: K23 DA022297
  • Agency: NIDA NIH HHS, Id: K23 DA022297-01A1
  • Agency: NIDA NIH HHS, Id: K23 DA022297-02
  • Agency: NIDA NIH HHS, Id: K23 DA022297-03
  • Agency: NIDA NIH HHS, Id: K24 DA022288
  • Agency: NIDA NIH HHS, Id: K24 DA022288
  • Agency: NIDA NIH HHS, Id: U10 DA013045
  • Agency: NIDA NIH HHS, Id: U10 DA022297
  • Agency: NIDA NIH HHS, Id: U10 DA13035
  • Agency: NIDA NIH HHS, Id: U10 DA13036
  • Agency: NIDA NIH HHS, Id: U10 DA13043
  • Agency: NIDA NIH HHS, Id: U10 DA13045
  • Agency: NIDA NIH HHS, Id: U10 DA13046
  • Agency: NIDA NIH HHS, Id: U10 DA13710
  • Agency: NIDA NIH HHS, Id: U10 DA13720
  • Agency: NIDA NIH HHS, Id: U10 DA13732
  • Agency: NIDA NIH HHS, Id: U10 DA15831

Mesh Terms

  • Adult
  • Analgesics, Opioid
  • Buprenorphine
  • Drug Combinations
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Naloxone
  • Narcotic Antagonists
  • Opioid-Related Disorders
  • Pain
  • Randomized Controlled Trials as Topic
  • Severity of Illness Index
  • Substance Withdrawal Syndrome